367 results on '"O’Driscoll, Caitriona M."'
Search Results
2. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer
3. Delivery of melarsoprol using folate-targeted PEGylated cyclodextrin-based nanoparticles for hepatocellular carcinoma
4. The blood-brain barrier in aging and neurodegeneration
5. Microbial-derived metabolites induce actin cytoskeletal rearrangement and protect blood-brain barrier function
6. Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy
7. Pre-Clinical Evaluation of a Modified Cyclodextrin-Based Nanoparticle for Intestinal Delivery of Liraglutide
8. A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?
9. In Vitro and In Silico ADME Prediction
10. Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease
11. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy
12. Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin
13. The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia
14. Cyclodextrin-siRNA conjugates as versatile gene silencing agents
15. Targeted Drug Delivery via Folate Receptors for the Treatment of Brain Cancer: Can the Promise Deliver?
16. Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo
17. Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells
18. A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor
19. Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin
20. Nano-Hydroxyapatite/PLGA Mixed Scaffolds as a Tool for Drug Development and to Study Metastatic Prostate Cancer in the Bone
21. Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
22. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery
23. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments
24. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: In vitro analysis
25. Delivering a disease-modifying treatment for Huntington's disease
26. Strategies to Mitigate and Treat Orthopaedic Device-Associated Infections
27. The gut microbiota is important for the maintenance of blood–cerebrospinal fluid barrier integrity
28. Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy
29. Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia
30. PEGylated cyclodextrins as novel siRNA nanosystems: Correlations between polyethylene glycol length and nanoparticle stability
31. Biophysical and Structural Characterisation of Nucleic Acid Complexes with Modified Cyclodextrins Using Circular Dichroism
32. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: Case studies with fenofibrate
33. Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system
34. 7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice
35. Co-Formulation of Amphiphilic Cationic and Anionic Cyclodextrins Forming Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukaemia
36. Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
37. Gastrointestinal gene delivery by cyclodextrins – In vitro quantification of extracellular barriers
38. Non-Viral Nanosystems for Gene and Small Interfering RNA Delivery to the Central Nervous System: Formulating the Solution
39. A novel lipid-based solid dispersion for enhancing oral bioavailability of Lycopene – In vivo evaluation using a pig model
40. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?
41. Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review
42. Biomimetic gold nanocomplexes for gene knockdown: Will gold deliver dividends for small interfering RNA nanomedicines?
43. Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport - In Vitro and In Vivo Studies
44. Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models Towards Therapeutic Significance
45. Lipid‐based Formulations
46. Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review
47. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models
48. A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer
49. Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model
50. The gut microbiota is important for the maintenance of blood–cerebrospinal fluid barrier integrity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.